Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin to reverse advanced type 1 diabetes demonstrate a potential new mechanism by which the BCG vaccine may restore the proper immune response to the insulin-secreting islet cells of the pancreas.
Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin to reverse advanced type 1 diabetes demonstrate a potential new mechanism by which the BCG vaccine may restore the proper immune response to the insulin-secreting islet cells of the pancreas.
Share this Article
Recommended